Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | TPMT | P51580 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6924772 | 0.85 | TDP1 (0.51) | ALDH1A1HPGDMAPTTDP1TPMT | |
| SCHEMBL11281015 | 0.81 | ALDH1A1 (0.38) | RAB9ANPC1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL7032033 | 0.81 | MAPT (0.51) | RAB9ANPC1MAPK1MAPTTDP1 | |
| SCHEMBL27189281 | 0.80 | ALDH1A1 (0.41) | RAB9ANPC1ALDH1A1HPGDMAPT | |
| SCHEMBL28770764 | 0.78 | HTR2A (0.40) | RAB9ANPC1MAPTTDP1TPMT | |
| SCHEMBL9239540 | 0.78 | LMNA (0.56) | RAB9ANPC1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL70469 | 0.78 | CYP3A4 (0.44) | ALDH1A1HPGDCYP3A4MAPK1MAPT | |
| SCHEMBL29997568 | 0.78 | TDP1 (0.44) | RAB9ANPC1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL2202238 | 0.78 | TDP1 (0.44) | RAB9ANPC1ALDH1A1HPGDCYP3A4 | |
| SCHEMBL9174235 | 0.76 | L3MBTL1 (0.38) | ALDH1A1HPGDMAPTKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8604021-B2 | Substituted arylamine compounds and methods of treatment | BECKER OREN (IL) | 2013-12-10 | — | — | US | disclosed |
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | BECKER OREN (IL) | 2012-05-10 | — | — | US | disclosed |
| US-7968538-B2 | Substituted arylamine compounds and methods of treatment | GALENEA CORP. (US) | 2011-06-28 | — | — | US | disclosed |
| EP-1856075-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | Epix Delaware, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | GALENEA CORPORATION | 2006-09-14 | — | — | US | disclosed |
| WO-2006081332-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND THEIR USE AS 5-HT6 MODULATORS | EPIX DELAWARE, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115850-A1 | SUBSTITUTED ARYLAMINE COMPOUNDS AND METHODS OF TREATMENT | HTR6, HTR2A, HTR3B | RAB9A 2608/4885NPC1 2713/4885ALDH1A1 1488/4885 |
| US-20060205737-A1 | Substituted arylamine compounds and methods of treatment | HTR6, HTR2A, HTR3B | RAB9A 2608/4885NPC1 2713/4885ALDH1A1 1488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.